-
Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering
-
Reata Pharma (RETA) Announces 2M Share Proposed Public Offering of Class A Common Stock
-
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
-
Pre-Open 10/15 (RETA) (AXAS) (UNH) Higher (PAGS) (GS) (BLMN) Lower (more...)
-
UPDATE: Reata Pharmaceuticals (RETA) PT Raised to 'Street High' $241 at Citi as Omav Upside Realized
-
Reata Pharmaceuticals (RETA) PT Raised to $194 at Citi
-
Reata Pharmaceuticals (RETA) PT Raised to $190 at Citi
-
Reata Pharma (RETA): KOL Positive on Bardoxolone's Potential in CKD - Citi
-
Reata Pharmaceuticals (RETA) PT Raised to $185 at Citi, Added to US Focus List
-
Reata Pharmaceuticals (RETA) PT Raised to $95 at Citi
-
Reata Pharmaceuticals (RETA) PT Lowered to $76 at Citi
-
Reata Pharmaceuticals (RETA) PT Lowered to $78 at Citi
-
Reata Pharma (RETA): 123% PT Increase - Citi
-
Reata Pharmaceuticals (RETA) PT Raised to $39 at Citi
-
Reata Pharma (RETA) Files Common Stock Shelf
-
Reata Pharmaceuticals, Inc. Announces Filing of Registration Statement for Proposed Public Offering
-
Reata Pharmaceuticals (RETA) Closes 6.33M Common Stock IPO; Includes Full Underwriter Overallotment
-
Reata Pharmaceuticals, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock
-
Reata Pharmaceuticals (RETA) IPO Opens Flat
-
Reata Pharma (RETA) Prices 5.5M Class A Common Stock IPO at $11/Share
-
Reata Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
-
Reata Pharmaceuticals (RETA) Files $80M Common Stock IPO

